Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer’s

About this update from Acumen Pharmaceuticals, Inc.

[{"type":"image","alt":"Today's Marketplace","displaySize":"","headline":null,"caption":"Today's Marketplace","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/97b88e39afce99baf7fef8515a6d4202"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Zi9wVOfBhOhrQXnlg42qCA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/97b88e39afce99baf7fef8515a6d4202","width":300,"height":300}},"lazy":false},{"type":"text","content":"NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with Acumen Pharmaceuticals (NASDAQ: ABOS) CEO Daniel O’Connell and Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. The pair joined Today’s Marketplace host Elizabeth Hart to discuss Alzheimer’s Disease.","length":352,"tagName":"p"},{"type":"text","content":"The full interview can be viewed online here.","length":45,"tagName":"p"},{"type":"text","content":"“In the U.S., we have over six million people diagnosed with active Alzheimer’s today, and worldwide, about 55 million,” said Clark.","length":132,"tagName":"p"},{"type":"text","content":"Dr. Clark went on to say that the economic impact of this devastating disease could seem “insurmountable at times,” explaining that the treatment and long-term care costs associated with Alzheimer's are about $360 billion dollars. And that does not even consider the time investment and productivity losses experienced by caregivers.","length":337,"tagName":"p"},{"type":"text","content":"Mr. O’Connell then explained that his company, Acumen Pharmaceuticals, is singularly focused on targeted Alzheimer’s therapies. “Acumen is focused on developing therapeutics for people living with Alzheimer's disease. We are advancing sabirnetug, which is a monoclonal antibody that was designed to target amyloid beta oligomers (AβOs), [a specific contributing factor in the disease.]”","length":390,"tagName":"p"},{"type":"text","content":"He continued to point out that the drug had positive results in their Phase I study, which indicated that sabirnetug had a good safety profile and showed the anticipated pharmacological effects on the AβOs targets in a short-term study.","length":236,"tagName":"p"},{"type":"text","content":"“We are n...

More updates from Acumen Pharmaceuticals, Inc.